Clinical Trials Logo

Filter by:
NCT ID: NCT02453256 Completed - Systemic Sclerosis Clinical Trials

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

focuSSced
Start date: November 20, 2015
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy and safety of tocilizumab compared with placebo in participants with SSc across approximately 120 planned global study sites. The study will consist of a 48-week, double-blind, placebo-controlled period followed by a 48-week open-label treatment period. Participants will be assigned, in a 1:1 ratio, to double-blind treatment with active tocilizumab or matching placebo. In the open-label period, eligible participants from either arm may receive active tocilizumab.

NCT ID: NCT02453165 Completed - Clinical trials for Surgical Wound Dehiscence

Vaginal Cuff Dehiscence Following Total Laparoscopic Hysterectomy: Laparoscopic vs. Transvaginal Cuff Closure

Start date: February 1, 2015
Phase: N/A
Study type: Interventional

Post-hysterectomy vaginal cuff dehiscence is a rare but threatening complication. The investigators will compare transvaginal versus laparoscopic closure of the vaginal vault at the end of a total laparoscopic hysterectomy, in order which of these two modalities of suturing is associated with a lower risk of dehiscence.

NCT ID: NCT02453009 Completed - Prostatic Neoplasms Clinical Trials

Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer

CHEIRON
Start date: October 2014
Phase: Phase 2
Study type: Interventional

The aim of this study is to verify if the addition of enzalutamide to docetaxel is able to improve the disease control in first line CRPC patients.

NCT ID: NCT02452515 Completed - Heart Failure Clinical Trials

A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction

CHIARA MIA 1
Start date: July 2015
Phase: Phase 2
Study type: Interventional

The purpose of the trial is the analysis of safety and tolerability of the chymase inhibitor BAY1142524 in comparison to placebo using a 2 weeks treatment period in clinically stable patients with left-ventricular dysfunction after myocardial infarction. BAY1142524 or placebo will be given on top of evidence-based standard of care for left-ventricular dysfunction after myocardial infarction. Primary objectives are the analysis of safety and tolerability as evidenced by the incidence and severity of adverse events. BAY1142524 will be administered in a parallel group design using four doses (5, 10, 25 mg twice daily, and 50 mg once daily). Each dose group consists of 9 patients treated with verum and 3 patients treated with placebo.

NCT ID: NCT02451592 Completed - Multiple Myeloma Clinical Trials

Fungemia in Hematologic Malignancies

Start date: January 2011
Phase: N/A
Study type: Observational

The purpose of this study is to determine the risk factors for fungemia in a population of patients diagnosed with hematologic malignancies and eligible for chemotherapy.

NCT ID: NCT02450539 Completed - Clinical trials for Non-Small Cell Lung Cancer Stage IV

A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer

Start date: August 6, 2015
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the effectiveness of the study drug known as abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.

NCT ID: NCT02450188 Completed - Clinical trials for Erectile Dysfunction

Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV)

STEDOV
Start date: March 2012
Phase: Phase 4
Study type: Interventional

The aim of the present study is to evaluate the efficacy of a combined approach with Vardenafil orodispersible and Cognitive Behavioural Sex Therapy in the treatment of Erectile Dysfunction, compared to medical only treatment, in terms of quality and duration of erection and couple's sexual satisfaction.

NCT ID: NCT02450058 Completed - Breast Cancer Clinical Trials

Adjuvant FEC Versus EP in Breast Cancer (MIG5)

MIG5
Start date: November 1996
Phase: Phase 3
Study type: Interventional

In this multicenter, randomized phase III trial, node positive early breast cancer patients are randomly assigned to receive either 6 cycles of FEC (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, on day 1, every three weeks) or 4 cycles of EP (epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, on day 1, every three weeks). The primary study endpoint is overall survival (OS). Secondary endpoints include toxicity and event free survival (EFS).

NCT ID: NCT02450019 Completed - Clinical trials for Nervous System Neoplasms

Protective Ventilation in Neurosurgery, a Pilot Study

NeuroVentOR
Start date: May 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effect size and variability of dural tension measured as intracranial pressure (ICP) below the dura of the surgical field in patients undergoing elective supra-tentorial surgery for brain neoplasms in patients alternatively ventilated with traditional high-volume-no-PEEP ventilation and protective low-volume-low-PEEP ventilation.

NCT ID: NCT02447692 Completed - Clinical trials for Acute Respiratory Failure

Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study

PROMIZING
Start date: September 14, 2016
Phase: N/A
Study type: Interventional

For adult patients with acute respiratory failure requiring invasive mechanical ventilation, does a ventilation strategy using proportional assist ventilation with load-adjustable gain factors (PAV+) result in a shorter duration of time spent on mechanical ventilation than a ventilation strategy using pressure support ventilation (PSV)?